Safety and immunogenicity of live attenuated human-bovine (UK) reassortant rotavirus vaccines with VP7-specificity for serotypes 1, 2, 3 or 4 in adults, children and infants

Mary Lou Clements-Mann; Mamodikoe K. Makhene; Jacek Mrukowicz; Peter F. Wright; Yasutaka Hoshino; Karen Midthun; Ellen Sperber; Ruth Karron; Albert Z. Kapikian

doi:10.1016/S0264-410X(98)00497-6

Safety and immunogenicity of live attenuated human-bovine (UK) reassortant rotavirus vaccines with VP7-specificity for serotypes 1, 2, 3 or 4 in adults, children and infants

Mary Lou Clements-Mann, Mamodikoe K. Makhene, Jacek Mrukowicz, Peter F. Wright, Yasutaka Hoshino, Karen Midthun, Ellen Sperber, Ruth Karron, Albert Z. Kapikian

Bloomberg School of Public Health

Research output: Contribution to journal › Article › peer-review

59 Scopus citations

Abstract

Live rotavirus vaccine candidates representing VP7 serotypes 1, 2, 3 or 4 derived by reassortment between bovine UK rotavirus and human rotavirus strains D, DS-1, P or ST3 were evaluated for safety and immunogenicity in adults, children and infants. Infection was defined by evidence of rotavirus shed in stools or a 4-fold or greater increase in serum rotavirus-specific IgA or IgG ELISA or plaque reduction neutralization antibody. A single oral dose (10^5.3 or 10^5.8 pfu) of reassortant virus was well tolerated and infected most infants: 10/20 (50%) by D x UK; 9/11 (82%) by DS-1 x UK; 8/10 (80%) by P x UK and 13/14 (93%) by ST3 x UK. All 14 infants given two doses of D x UK were infected. These findings demonstrating satisfactory levels of attenuation, safety, infectivity and immunogenicity of each reassortant in infants warrant additional studies of a candidate vaccine containing these four strains.

Original language	English (US)
Pages (from-to)	2715-2725
Number of pages	11
Journal	Vaccine
Volume	17
Issue number	20-21
DOIs	https://doi.org/10.1016/S0264-410X(98)00497-6
State	Published - Jun 4 1999

Keywords

Diarrheal vaccines
Human-bovine reassortant rotavirus vaccines
Live attenuated virus vaccines
Pediatric vaccines
Rotavirus vaccines

ASJC Scopus subject areas

Molecular Medicine
Immunology and Microbiology(all)
veterinary(all)
Public Health, Environmental and Occupational Health
Infectious Diseases

Access to Document

10.1016/S0264-410X(98)00497-6

Cite this

Clements-Mann, M. L., Makhene, M. K., Mrukowicz, J., Wright, P. F., Hoshino, Y., Midthun, K., Sperber, E., Karron, R., & Kapikian, A. Z. (1999). Safety and immunogenicity of live attenuated human-bovine (UK) reassortant rotavirus vaccines with VP7-specificity for serotypes 1, 2, 3 or 4 in adults, children and infants. Vaccine, 17(20-21), 2715-2725. https://doi.org/10.1016/S0264-410X(98)00497-6

Safety and immunogenicity of live attenuated human-bovine (UK) reassortant rotavirus vaccines with VP7-specificity for serotypes 1, 2, 3 or 4 in adults, children and infants. / Clements-Mann, Mary Lou; Makhene, Mamodikoe K.; Mrukowicz, Jacek et al.
In: Vaccine, Vol. 17, No. 20-21, 04.06.1999, p. 2715-2725.

Research output: Contribution to journal › Article › peer-review

Clements-Mann, ML, Makhene, MK, Mrukowicz, J, Wright, PF, Hoshino, Y, Midthun, K, Sperber, E, Karron, R & Kapikian, AZ 1999, 'Safety and immunogenicity of live attenuated human-bovine (UK) reassortant rotavirus vaccines with VP7-specificity for serotypes 1, 2, 3 or 4 in adults, children and infants', Vaccine, vol. 17, no. 20-21, pp. 2715-2725. https://doi.org/10.1016/S0264-410X(98)00497-6

@article{8ac9e2f12b624eae96faa67724502deb,

title = "Safety and immunogenicity of live attenuated human-bovine (UK) reassortant rotavirus vaccines with VP7-specificity for serotypes 1, 2, 3 or 4 in adults, children and infants",

abstract = "Live rotavirus vaccine candidates representing VP7 serotypes 1, 2, 3 or 4 derived by reassortment between bovine UK rotavirus and human rotavirus strains D, DS-1, P or ST3 were evaluated for safety and immunogenicity in adults, children and infants. Infection was defined by evidence of rotavirus shed in stools or a 4-fold or greater increase in serum rotavirus-specific IgA or IgG ELISA or plaque reduction neutralization antibody. A single oral dose (105.3 or 105.8 pfu) of reassortant virus was well tolerated and infected most infants: 10/20 (50%) by D x UK; 9/11 (82%) by DS-1 x UK; 8/10 (80%) by P x UK and 13/14 (93%) by ST3 x UK. All 14 infants given two doses of D x UK were infected. These findings demonstrating satisfactory levels of attenuation, safety, infectivity and immunogenicity of each reassortant in infants warrant additional studies of a candidate vaccine containing these four strains.",

keywords = "Diarrheal vaccines, Human-bovine reassortant rotavirus vaccines, Live attenuated virus vaccines, Pediatric vaccines, Rotavirus vaccines",

author = "Clements-Mann, {Mary Lou} and Makhene, {Mamodikoe K.} and Jacek Mrukowicz and Wright, {Peter F.} and Yasutaka Hoshino and Karen Midthun and Ellen Sperber and Ruth Karron and Kapikian, {Albert Z.}",

note = "Funding Information: We thank Romero Paredes, Dr. Modena Wilson, Mary Jett-Goheen, Pam Nehring, Kathleen Gay, Kathleen MacLeod, Barbara Burns, Roberta Casey and Anna Speaks at the Johns Hopkins University Center for Immunization Research; Juliette Thompson and Sharon Tollefson at the Vanderbilt Vaccine Center and Mariam Watson and Dr. Xiao-Yi Yan at the National Institute of Allergy and Infectious Diseases for their assistance with these studies. Also, we are grateful to Alice Brogden for manuscript preparation and Dr. Robert Chanock for reviewing the manuscript. Sources of financial support: National Institutes of Health contracts No. 1-AI-15095 and No. 1-AI-05050; JM was supported by a fellowship from the International Pediatric Research Foundation.",

year = "1999",

month = jun,

day = "4",

doi = "10.1016/S0264-410X(98)00497-6",

language = "English (US)",

volume = "17",

pages = "2715--2725",

journal = "Vaccine",

issn = "0264-410X",

publisher = "Elsevier BV",

number = "20-21",

}

TY - JOUR

T1 - Safety and immunogenicity of live attenuated human-bovine (UK) reassortant rotavirus vaccines with VP7-specificity for serotypes 1, 2, 3 or 4 in adults, children and infants

AU - Clements-Mann, Mary Lou

AU - Makhene, Mamodikoe K.

AU - Mrukowicz, Jacek

AU - Wright, Peter F.

AU - Hoshino, Yasutaka

AU - Midthun, Karen

AU - Sperber, Ellen

AU - Karron, Ruth

AU - Kapikian, Albert Z.

N1 - Funding Information: We thank Romero Paredes, Dr. Modena Wilson, Mary Jett-Goheen, Pam Nehring, Kathleen Gay, Kathleen MacLeod, Barbara Burns, Roberta Casey and Anna Speaks at the Johns Hopkins University Center for Immunization Research; Juliette Thompson and Sharon Tollefson at the Vanderbilt Vaccine Center and Mariam Watson and Dr. Xiao-Yi Yan at the National Institute of Allergy and Infectious Diseases for their assistance with these studies. Also, we are grateful to Alice Brogden for manuscript preparation and Dr. Robert Chanock for reviewing the manuscript. Sources of financial support: National Institutes of Health contracts No. 1-AI-15095 and No. 1-AI-05050; JM was supported by a fellowship from the International Pediatric Research Foundation.

PY - 1999/6/4

Y1 - 1999/6/4

N2 - Live rotavirus vaccine candidates representing VP7 serotypes 1, 2, 3 or 4 derived by reassortment between bovine UK rotavirus and human rotavirus strains D, DS-1, P or ST3 were evaluated for safety and immunogenicity in adults, children and infants. Infection was defined by evidence of rotavirus shed in stools or a 4-fold or greater increase in serum rotavirus-specific IgA or IgG ELISA or plaque reduction neutralization antibody. A single oral dose (105.3 or 105.8 pfu) of reassortant virus was well tolerated and infected most infants: 10/20 (50%) by D x UK; 9/11 (82%) by DS-1 x UK; 8/10 (80%) by P x UK and 13/14 (93%) by ST3 x UK. All 14 infants given two doses of D x UK were infected. These findings demonstrating satisfactory levels of attenuation, safety, infectivity and immunogenicity of each reassortant in infants warrant additional studies of a candidate vaccine containing these four strains.

AB - Live rotavirus vaccine candidates representing VP7 serotypes 1, 2, 3 or 4 derived by reassortment between bovine UK rotavirus and human rotavirus strains D, DS-1, P or ST3 were evaluated for safety and immunogenicity in adults, children and infants. Infection was defined by evidence of rotavirus shed in stools or a 4-fold or greater increase in serum rotavirus-specific IgA or IgG ELISA or plaque reduction neutralization antibody. A single oral dose (105.3 or 105.8 pfu) of reassortant virus was well tolerated and infected most infants: 10/20 (50%) by D x UK; 9/11 (82%) by DS-1 x UK; 8/10 (80%) by P x UK and 13/14 (93%) by ST3 x UK. All 14 infants given two doses of D x UK were infected. These findings demonstrating satisfactory levels of attenuation, safety, infectivity and immunogenicity of each reassortant in infants warrant additional studies of a candidate vaccine containing these four strains.

KW - Diarrheal vaccines

KW - Human-bovine reassortant rotavirus vaccines

KW - Live attenuated virus vaccines

KW - Pediatric vaccines

KW - Rotavirus vaccines

UR - http://www.scopus.com/inward/record.url?scp=0033522950&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033522950&partnerID=8YFLogxK

U2 - 10.1016/S0264-410X(98)00497-6

DO - 10.1016/S0264-410X(98)00497-6

M3 - Article

C2 - 10418923

AN - SCOPUS:0033522950

SN - 0264-410X

VL - 17

SP - 2715

EP - 2725

JO - Vaccine

JF - Vaccine

IS - 20-21

ER -

Safety and immunogenicity of live attenuated human-bovine (UK) reassortant rotavirus vaccines with VP7-specificity for serotypes 1, 2, 3 or 4 in adults, children and infants

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this